The COVID Advisor

As rates of infection with influenza and RSV rose in fall/winter 2022, FLCCC adapted the I-PREVENT protocol to include prevention against these viruses. The interventions recommended are likely to reduce the risk and severity of infection with COVID-19, influenza, and RSV infections as well as the common cold. It should be noted that the medications included in the I-PREVENT protocol are inexpensive, safe, and widely available. This protocol includes a section for pre-exposure (long-term) as well as a post-exposure (acute, short-term). About this Protocol The information in this document is our recommended approach to COVID-19 based on the best (and most recent) literature. It is provided as guidance to healthcare providers worldwide on the early treatment of COVID-19. Patients should always consult with their provider before starting any medical treatment. New medications may be added and/or changes made to doses of existing medications as further evidence emerges. Ple

Please enjoy this continuing medical education lecture delivered at 40th Cellular Detoxification Conference sponsored by International College of Integrative Medicine in Indianapolis, Indianana, on September 7 2024. There are no medicine grand rounds or primary care conferences addressing this topic. It is a white space in medicine where no academic medical center has a fundamental approach to handling about 5-10% of the population suffering from post-acute sequalae after recurrent SARS-CoV-2 infection or COVID-19 infection. Both load the body with pathogenic Spike protein which incites inflammation, oxidative stress, coagulation, and all the downstream effects that result in symptoms. BSD=Base Spike Detoxification Because I have taken the ultimate accountability for McCullough Protocol Base Spike Detoxification (BSD) by publishing and copyrighting it in my own name, I can tell you first hand I get feedback about perceived safety and efficacy on a regular basis from all over the world.

If you are confused about the recommendations made by different professional groups for the COVID-19 pandemic, you've come to the right place.  The U.S. Centers for Disease Control and Prevention (CDC) said that COVID-19 levels across the United States are currently “very high” in more than half of the states, with Omicron variant KP.3.1.1 accounting for about half of all cases; for the two-week period ending September 14, 2024 ( source ). A spokesperson for the CDC told The Epoch Times that the KP.3.1.1 “is very similar to other circulating variants in the United States, and all current lineages are descendants of JN.1, which emerged in late 2023.” Some media outlets have referred to both the KP.2 and KP.3 variants as “FLiRT,” (which stands for mutations in the virus's spike protein at positions designated "F for L" and "R for T"). Are the current treatment options still relevant? The number of options for the treatment of COVID-19 has increa

A new COVID-19 variant called XEC has begun to spread in multiple regions worldwide and the U.S. Centers for Disease Control and Prevention (CDC) said that no specific symptoms are associated with the variant. The variant first appeared in Berlin in late June and has spread across Germany, France, Denmark, and Netherlands, said a report from data integration specialist Mike Honey, citing the Global Initiative on Sharing All Influenza Data. CDC spokeswoman Rosa Norman told The Epoch Times on Monday that the CDC is monitoring “the emergence of variants in the population,” including XEC, and that “specific cases cannot be associated with specific variants.” “Please continue to check the COVID Data Tracker for updated information on the common variants we’re seeing the U.S,” she said. Symptoms When asked whether XEC may produce different or more severe symptoms, Norman said the CDC is not aware of any “specific symptoms” associated with the variant or “co-circulating” strains. A global he